The Association Between Short-Acting $ β_{2} $-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia
Introduction In Australia, short-acting $ β_{2} $-agonists (SABA) are available both over the counter (OTC) and on prescription. This ease of access may impact SABA use in the Australian population. Our aim was to assess patterns and outcome associations of prescribed, acquired OTC and reported use of SABA by Australians with asthma. Methods This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated. Results 92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73–3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13–6.55) more likely to have poor asthma control than those who reported using 1–2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07–7.26) times more severe exacerbations than those prescribed 1–2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication. Conclusion Both self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 3 vom: 04. Feb., Seite 1262-1283 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Price, David [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Asthma management |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s12325-023-02746-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05483760X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05483760X | ||
| 003 | DE-627 | ||
| 005 | 20240221064703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240221s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02746-0 |2 doi | |
| 035 | |a (DE-627)SPR05483760X | ||
| 035 | |a (SPR)s12325-023-02746-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Price, David |e verfasserin |0 (orcid)0000-0002-9728-9992 |4 aut | |
| 245 | 1 | 4 | |a The Association Between Short-Acting $ β_{2} $-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Introduction In Australia, short-acting $ β_{2} $-agonists (SABA) are available both over the counter (OTC) and on prescription. This ease of access may impact SABA use in the Australian population. Our aim was to assess patterns and outcome associations of prescribed, acquired OTC and reported use of SABA by Australians with asthma. Methods This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated. Results 92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73–3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13–6.55) more likely to have poor asthma control than those who reported using 1–2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07–7.26) times more severe exacerbations than those prescribed 1–2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication. Conclusion Both self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use. | ||
| 650 | 4 | |a Short-acting β2-agonists |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Asthma management |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Over-the-counter medication |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prescription patterns |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Asthma outcomes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Jenkins, Christine |4 aut | |
| 700 | 1 | |a Hancock, Kerry |4 aut | |
| 700 | 1 | |a Vella, Rebecca |4 aut | |
| 700 | 1 | |a Heraud, Florian |4 aut | |
| 700 | 1 | |a Le Cheng, Porsche |4 aut | |
| 700 | 1 | |a Murray, Ruth |4 aut | |
| 700 | 1 | |a Beekman, Maarten |4 aut | |
| 700 | 1 | |a Bosnic-Anticevich, Sinthia |4 aut | |
| 700 | 1 | |a Botini, Fabio |4 aut | |
| 700 | 1 | |a Carter, Victoria |4 aut | |
| 700 | 1 | |a Catanzariti, Angelina |4 aut | |
| 700 | 1 | |a Doan, Joe |4 aut | |
| 700 | 1 | |a Fletton, Kirsty |4 aut | |
| 700 | 1 | |a Kichkin, Ata |4 aut | |
| 700 | 1 | |a Le, Thao |4 aut | |
| 700 | 1 | |a Le Lievre, Chantal |4 aut | |
| 700 | 1 | |a Lau, Chi Ming |4 aut | |
| 700 | 1 | |a Novic, Dominique |4 aut | |
| 700 | 1 | |a Pakos, John |4 aut | |
| 700 | 1 | |a Ranasinghe, Kanchanamala |4 aut | |
| 700 | 1 | |a Roussos, Alexander |4 aut | |
| 700 | 1 | |a Samuel-King, Josephine |4 aut | |
| 700 | 1 | |a Sharma, Anita |4 aut | |
| 700 | 1 | |a Stewart, Deb |4 aut | |
| 700 | 1 | |a Willet, Bruce |4 aut | |
| 700 | 1 | |a Bateman, Eric |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 41(2024), 3 vom: 04. Feb., Seite 1262-1283 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:3 |g day:04 |g month:02 |g pages:1262-1283 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-023-02746-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 3 |b 04 |c 02 |h 1262-1283 | ||